Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: A pooled analysis of randomized clinical trials

Stroke

Volumn 36, Issue 1, 2005, Pages 62-65

  Kent, David M ^a   Price, Lori Lyn ^a   Ringleb, Peter ^b   Hill, Michael D ^c   Selker, Harry P ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Clinical trials; Outcome; Sex factors; Stroke, acute; Thrombolytic therapy

Indexed keywords

ALTEPLASE; PLACEBO;

ADULT; AGE; AGED; ARTICLE; BLOOD CLOTTING; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ACUTE DISEASE; AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DATABASES, FACTUAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; SEX FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 11144226333     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000150515.15576.29     Document Type: Article

References (31)

1. Bouser MG, Stroke in women. Circulation. 1999;99:463-467.
2. Holyroyd-Leduc JM, Kapral MK, Austin PC, Tu JV. Sex differences and similarities in the management and outcome of stroke patients. Stroke. 2000;31:1833-1837.
3. Ramani S, Byrne-Logan S, Freund KM, Ash A, Yu W, Moskowitz MA. Gender differences in the treatment of cerebrovascular disease. J Am Geriatr Soc. 2000;48:741-745.
4. Kain K, Carter AM, Bamford JM, Grant PJ, Catto AJ. Gender differences in coagulation and fibrinolysis in white subjects with acute ischemic stroke. J Thromb Haemost. 2003;1:390-392.
5. Kain K, Catto AJ, Carter AM, Young J, Bamford J, Bavington J, Grant PJ. Decreased fibrinolytic potential in South Asian women with ischaemic cerebrovascular disease. Br J Haematol. 2001;114:155-161.
6. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY, Bovill EG. Markers of thrombin with platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the Stroke Prevention in Atrial Fibrillation III Study. Stroke. 1999;30:2547-2553.
7. Kent DM, Ruthazer R, Bluhmki E, Selker HP. Beyond the three-hour time-window: mulitvariable patient-selection for thrombolytic therapy in acute ischemic stroke (Abstract). Ann Neurol. 2003;54(Suppl 7):S18.
8. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
9. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0-to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. 2000;31:811-816.
10. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA. 1999;282:2019-2026.
11. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-I251.
12. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marier JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363;768-774.
13. Tilley BC. Marier J. Geller NL. Lu M. Legier J Brott T Lyden P Grotta J. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke. 1996;27:2136-2142.
14. Pexman JH, Barber PA, Hill MD, Sevick RJ, Demchuk AM, Hudon ME, Hu WY, Buchan AM. Use of the Alberta Stroke Program Early CT Score (ASPECTS) for assessing CT scans in patients with acute stroke. AJNR Am J Neuroradiol 2001;22;1534-1542.
15. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000;355:1670-1674.
16. Marier JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, Broderick JP, Levine SR, Frankel MP, Horowitz SH, Haley EC Jr, Lewandowski CA, Kwiatkowski TP. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. 2000;55:1649-1655.
17. Broderick J, Lu M, Jackson C, Pancioli A, Tilley BC, Fagan SC, Kothari R, Levine SR, Marier JR, Lyden PD, Haley EC Jr, Brott T, Grotta JC; NINDS t-PA Stroke Study Group. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol. 2001;49:736-744.
18. Kent DM, Ruthazer R, Selker HP. Are some patients likely to benefit from recombinant tissue-type plasminogen activator for acute ischemic stroke even beyond 3 hours from symptom onset? Stroke. 2003;3:464-467.
19. Wyller TB, Sodring KM, Sveen U, Ljunggren AE, Bautz-Holtzer E Are there gender differences in functional outcome after stroke? Clin Rehabil. 1997;11:171-179.
20. Weimar C, Ziegler A, Konig IR, Diener HC. Predicting functional outcome and survival after acute ischemic stroke. J Neurol. 2002;249:888-895.
21. Lofgren B, Nyberg L, Osterlind PO, Gustafson Y. In-patient rehabilitation after stroke: outcome and factors associated with improvement. Disabil. Rehabil. 1998;20:55-61.
22. Glader EL, Stegmayr B, Norrving B, Terent A, Hulter-Asberg K, Wester PO, Asplund K; Riks-Stroke Collaboration. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke. 2003;34:1970-1975.
23. Anonymous. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke. 1997;28:2119-2125.
24. Ribó M, Montaner J, Molina CA, Arenillas JF, Rubiera M, Monasterio J, Huertas R, Santamarina E, Mauriño J, Alvarez-Sabín J. Baseline plasma PAI-1 level predicts recanalization, hemorrhagic transformation, and outcome in tPA-treated patients. Stroke. 2004;35:292.
25. Roof RL, Hall ED. Gender differences in acute CNS trauma and stroke: neuroprotective effects of estrogen and progesterone. J Neurotrauma. 2000;17:367-388.
26. Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab. 2000;20:631-652.
27. Roquer J, Campello AR, Gomis, M. Sex differences in first-ever acute stroke. Stroke. 2003;34:1581-1585.
28. Labiche LA, Chan W, Saldin KR, Morgenstern LB. Sex and acute stroke presentation. Ann Emerg Med. 2002;40:453-460.
29. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals, Stroke. 2001;32:1832-1840.
30. Giampaoli S. Epidemiology of major age-related diseases in women compared to men. Aging. 2000;12:93-105.
31. Guralnik JM, Balfour JL, Volpato S. The ratio of older women to men: historical perspectives and cross-national comparisons. Aging. 2000;12:321-322.